コンテンツへスキップ
Merck
  • Identification of two novel immunodominant UreB CD4(+) T cell epitopes in Helicobacter pylori infected subjects.

Identification of two novel immunodominant UreB CD4(+) T cell epitopes in Helicobacter pylori infected subjects.

Vaccine (2013-01-12)
Wu-Chen Yang, Li Chen, Hai-Bo Li, Bin Li, Jian Hu, Jin-Yong Zhang, Shi-Ming Yang, Quan-Ming Zou, Hong Guo, Chao Wu
要旨

An epitope-based vaccine is a promising option for treating Helicobacter pylori (H. pylori) infection. Epitope mapping is the first step in designing an epitope-based vaccine. A pivotal role of CD4(+) T cells in protection against H. pylori has been accepted, but few Th epitopes have been identified. In this study, two novel UreB CD4(+) T cell epitopes were identified using PBMCs obtained from two H. pylori infected subjects. We determined the restriction molecules by antibody blocking and used various Epstein-Barr virus-transformed B lymphocyte cell lines (BLCLs) with different HLA alleles as APCs to present peptides to CD4(+) T cells. These epitopes were DRB1*1404-restricted UreB(373-385) and DRB1*0803-restricted UreB(438-452). The T cells specific to these epitopes not only recognized autologous DCs loaded with recombinant UreB but also those pulsed with H. pylori whole cell lysates, suggesting that these epitope peptides are naturally processed. These epitopes have important value for designing an effective H. pylori vaccine.

材料
製品番号
ブランド
製品内容

Sigma-Aldrich
ウレアーゼ Canavalia ensiformis(タチナタマメ)由来, Type III, powder, 15,000-50,000 units/g solid
Sigma-Aldrich
ウレアーゼ Canavalia ensiformis(タチナタマメ)由来, Type IX, powder, 50,000-100,000 units/g solid
Sigma-Aldrich
ウレアーゼ Canavalia ensiformis(タチナタマメ)由来, powder, ~1 U/mg
Sigma-Aldrich
ウレアーゼ Canavalia ensiformis(タチナタマメ)由来, Type III, glycerol solution, 500-800 units/mL
Sigma-Aldrich
ウレアーゼ Canavalia ensiformis(タチナタマメ)由来, Type C-3, powder, ≥600,000 units/g solid
Sigma-Aldrich
ウレアーゼ Canavalia ensiformis(タチナタマメ)由来, powder, white, ~8 U/mg
Sigma-Aldrich
ウレアーゼ Canavalia ensiformis(タチナタマメ)由来